{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:26:26Z","timestamp":1791919586685,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jsps.2023.101931","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T19:27:30Z","timestamp":1703100450000},"page":"101931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia"],"prefix":"10.1007","volume":"32","author":[{"given":"Luma","family":"Al-Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5445-3628","authenticated-orcid":false,"given":"Raad J.","family":"Al-Ani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3140-4038","authenticated-orcid":false,"given":"Maysaa M.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-1220","authenticated-orcid":false,"given":"Alaa M.","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5277-5703","authenticated-orcid":false,"given":"Duaa A.","family":"Abuarqoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1040-3156","authenticated-orcid":false,"given":"Bashaer","family":"Abu-Irmaileh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-7446","authenticated-orcid":false,"given":"Abdallah Y.","family":"Naser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4372-997X","authenticated-orcid":false,"given":"Manal M.","family":"Najdawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7991-3827","authenticated-orcid":false,"given":"Manal M.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1005-7943","authenticated-orcid":false,"given":"Jamal","family":"Alyoussef Alkrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"3","key":"10.1016\/j.jsps.2023.101931_b0005","doi-asserted-by":"crossref","first-page":"909","DOI":"10.18596\/jotcsa.1092553","article-title":"Synthesis and Biological Evaluation of Furyl-Carboxamide Derivatives as Potential Anticancer Agents","volume":"9","author":"Al-Sammarra'e","year":"2022","journal-title":"JOTCSA"},{"issue":"10","key":"10.1016\/j.jsps.2023.101931_b0010","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review","volume":"34","author":"An","year":"2010","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.jsps.2023.101931_b0015","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jsps.2023.101931_b0020","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s11739-018-1957-0","article-title":"Vitamin D and tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"13","author":"Campiotti","year":"2018","journal-title":"Intern. Emerg. Med."},{"issue":"3","key":"10.1016\/j.jsps.2023.101931_b0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.jsps.2023.101931_b0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","article-title":"Natural history and staging of chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"6","key":"10.1016\/j.jsps.2023.101931_b0035","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","article-title":"Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines","volume":"32","author":"Deguchi","year":"2008","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.jsps.2023.101931_b0040","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jsps.2023.101931_b0045","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2017.02.015","article-title":"Vitamin D analogues: Potential use in cancer treatment","volume":"112","author":"Duffy","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jsps.2023.101931_b0050","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1124\/mol.104.008730","article-title":"Superagonistic action of 14-epi-analogs of 1,25-dihydroxyvitamin D explained by vitamin D receptor-coactivator interaction","volume":"67","author":"Eelen","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.jsps.2023.101931_b0055","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11899-015-0248-3","article-title":"Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors","volume":"10","author":"Eide","year":"2015","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"8","key":"10.1016\/j.jsps.2023.101931_b0060","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jsps.2019.10.005","article-title":"Evaluation of oxidative stress responses in human circulating blood cells after imatinib mesylate treatment\u2013Implications to its mechanism of action","volume":"27","author":"Gajski","year":"2019","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.jsps.2023.101931_b0065","first-page":"1","article-title":"I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition","volume":"14","author":"Gao","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.jsps.2023.101931_b0070","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4082\/kjfm.2015.36.5.197","article-title":"An overview and update of chronic myeloid leukemia for primary care physicians","volume":"36","author":"Granatowicz","year":"2015","journal-title":"Korean J. Fam. Med."},{"issue":"9","key":"10.1016\/j.jsps.2023.101931_b0075","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-15-2290","article-title":"GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation","volume":"76","author":"Gupta","year":"2016","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.jsps.2023.101931_b0080","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3390\/cancers12051242","article-title":"Long-term survival, vascular occlusive events and efficacy biomarkers of first-line treatment of CML: A meta-analysis","volume":"12","author":"Haguet","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.jsps.2023.101931_b0085","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jsps.2023.101931_b0090","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jsps.2023.101931_b0095","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/bloodadvances.2021004958","article-title":"Impact of vitamin D level at diagnosis and transplantation on the prognosis of hematological malignancy: A meta-analysis","volume":"6","author":"Ito","year":"2022","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.jsps.2023.101931_b0100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ajh.24275","article-title":"Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring","volume":"91","author":"Jabbour","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.jsps.2023.101931_b0105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.jsps.2023.101931_b0110","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s00204-013-1065-x","article-title":"Statistical evaluation of toxicological assays: Dunnett or Williams test-take both","volume":"87","author":"Jaki","year":"2013","journal-title":"Arch. Toxicol."},{"issue":"4","key":"10.1016\/j.jsps.2023.101931_b0115","first-page":"1","article-title":"Exploring vitamin D metabolism and function in cancer","volume":"50","author":"Jeon","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.jsps.2023.101931_b0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4274\/balkanmedj.galenos.2018.2017.1244","article-title":"Cytotoxic effects of some flavonoids and Imatinib on the K562 chronic myeloid leukemia cell line: Data analysis using the combination index method","volume":"36","author":"Kal\u0131ndemirta\u015f","year":"2019","journal-title":"Balkan Med. J."},{"issue":"1","key":"10.1016\/j.jsps.2023.101931_b0125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","article-title":"Dasatinib: A review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jsps.2023.101931_b0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4097\/kjae.2017.70.1.22","article-title":"Understanding one-way ANOVA using conceptual figures","volume":"70","author":"Kim","year":"2017","journal-title":"Korean J. Anesthesiol."},{"issue":"3","key":"10.1016\/j.jsps.2023.101931_b0135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/ejh.12818","article-title":"Vitamin D in hematological disorders and malignancies","volume":"98","author":"Kulling","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jsps.2023.101931_b0140","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4161\/cc.23846","article-title":"Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system","volume":"12","author":"Ma","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jsps.2023.101931_b0145","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/bs.vh.2015.11.003","article-title":"Mechanistic insights of vitamin D anticancer effects","volume":"100","author":"Ma","year":"2016","journal-title":"Vitam. Horm."},{"issue":"3","key":"10.1016\/j.jsps.2023.101931_b0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.11613\/BM.2011.029","article-title":"Multiple comparison analysis testing in ANOVA","volume":"21","author":"McHugh","year":"2011","journal-title":"Biochem. Med. (zagreb)"},{"issue":"17","key":"10.1016\/j.jsps.2023.101931_b0155","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1158\/1078-0432.CCR-13-3247","article-title":"Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients Phase I","volume":"20","author":"Medioni","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.jsps.2023.101931_b0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol. Methods"},{"issue":"4","key":"10.1016\/j.jsps.2023.101931_b0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/ERC-16-0463","article-title":"Vitamin D receptor as a target for breast cancer therapy","volume":"24","author":"Murray","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"issue":"22","key":"10.1016\/j.jsps.2023.101931_b0170","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.3390\/ijms20225616","article-title":"Druggable biochemical pathways and potential therapeutic alternatives to target leukemic stem cells and eliminate the residual disease in chronic myeloid leukemia","volume":"20","author":"Muselli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jsps.2023.101931_b0175","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/nu12061798","article-title":"Vitamin D-induced molecular mechanisms to potentiate cancer therapy and to reverse drug-resistance in cancer cells","volume":"12","author":"Negri","year":"2020","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.jsps.2023.101931_b0180","first-page":"481","article-title":"The role of vitamin D in cancer prevention","volume":"13","author":"Ness","year":"2015","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.jsps.2023.101931_b0185","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/ijc.26279","article-title":"Inecalcitol, an analog of 1\u03b1,25(OH)(2)D(3), induces growth arrest of androgen-dependent prostate cancer cells","volume":"130","author":"Okamoto","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.jsps.2023.101931_b0190","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s11033-021-06141-2","article-title":"Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells","volume":"48","author":"Ozkan","year":"2021","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.jsps.2023.101931_b0195","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clnu.2016.01.021","article-title":"Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia","volume":"36","author":"Radujkovic","year":"2016","journal-title":"Clin. Nutr."},{"issue":"75","key":"10.1016\/j.jsps.2023.101931_b0200","doi-asserted-by":"crossref","first-page":"47297","DOI":"10.1039\/C7RA07257K","article-title":"Development of a series of bis-triazoles as G-quadruplex ligands","volume":"7","author":"Saleh","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.jsps.2023.101931_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/18741045-v16-e2207200","article-title":"Biological Evaluation and Reverse Pharmacophore Mapping of Innovative Bis-Triazoles as Promising Anticancer Agents","volume":"16","author":"Saleh","year":"2022","journal-title":"The Open Med. Chem. J."},{"issue":"1","key":"10.1016\/j.jsps.2023.101931_b0210","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/cimb45010014","article-title":"In Vitro Anticancer Properties of Novel Bis-Triazoles","volume":"45","author":"Saleh","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"3","key":"10.1016\/j.jsps.2023.101931_b0215","first-page":"209","article-title":"High prevalence of vitamin D deficiency in newly diagnosed acute myeloid leukemia patients and its adverse outcome","volume":"11","author":"Seyedalipour","year":"2017","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"10.1016\/j.jsps.2023.101931_b0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/BLCTT.S48319","article-title":"Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib","volume":"2014","author":"Shoumariyeh","year":"2014","journal-title":"Blood Lymphat. Cancer: Targets and Therapy"},{"issue":"3","key":"10.1016\/j.jsps.2023.101931_b0225","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1586\/14737140.2016.1151356","article-title":"Imatinib mesylate in chronic myeloid leukemia: Frontline treatment and long-term outcomes","volume":"16","author":"Stagno","year":"2016","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"10.1016\/j.jsps.2023.101931_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2023.123392","article-title":"Identifying synergistic combinations of Doxorubicin-Loaded polyquercetin nanoparticles and natural Products: Implications for breast cancer therapy","volume":"645","author":"Sunoqrot","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jsps.2023.101931_b0235","doi-asserted-by":"crossref","unstructured":"Turhan, A.G., Johnson Ansah, H., Hugues, P., Debord, C., Delansorne, R., Guerci-Bresler, A., Lamartinie, J., Bennaceur-Griscelli, A., 2015. Vitamin D3 analog Inecalcitol synergizes with tyrosine kinase inhibitors (TKI) and selectively inhibit the growth of chronic myeloid leukemia (CML) progenitors: Development of a clinically applicable leukemic stem cell targeting strategy. Cancer Res. 75 (15 Supplement), 2633-2633. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-2633.","DOI":"10.1158\/1538-7445.AM2015-2633"},{"issue":"10","key":"10.1016\/j.jsps.2023.101931_b0240","first-page":"2673","article-title":"Two novel 14-epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo","volume":"60","author":"Verlinden","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsps.2023.101931_b0245","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fendo.2012.00058","article-title":"Vitamin D and Cancer","volume":"3","author":"Vuolo","year":"2012","journal-title":"Front. Endocrinol. (lausanne)"},{"issue":"47","key":"10.1016\/j.jsps.2023.101931_b0250","first-page":"1","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"J. Hematol. Oncol."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016423004267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016423004267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:31:03Z","timestamp":1736184663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016423004267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1319016423004267"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2023.101931","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2023.101931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}],"article-number":"101931"}}